Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Vanessa Carle is Secretary at Lexaria Bioscience. OQRO lists 1 transaction filed with the SEC under this name, the latest on Jul 30, 2025, each linked to the official Form 4.
Secretary
Disclosures on record
1
Companies involved
1
As of the latest filing on , Vanessa Carle reported holding 750 shares of Lexaria Bioscience (LEXX), worth about $3K at the last close of $4 (Nov 20, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Lexaria Bioscience LEXX | 750 | 750 direct | $4 | $3K | Jul 29, 2025 |
Is this Vanessa Carle’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
1 buy, median −2.2 pts vs S&P 500, beat it 0 of 1 time.
Average −2.2 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Jul 30, 2025 to Jul 30, 2025, measured from the first close after the filing. Past results, not a forecast.
1 purchase disclosed; 0% of the 1 measured at 90 days finished ahead of the index.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 83 ranked insiders is −6.8 pts (median, against the S&P 500).
Equal weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Jul 29, 2025Bought~$683disclosed Jul 30
DetailsOfficial recordVanessa Carle bought shares on the open market in 2025. Sales in 1 of the 3 years since 2024.
Vanessa Carle reported 1 open-market purchase and 1 sale since 2024; purchases in 2025.
| Year | Bought | Sold |
|---|---|---|
| 2025 | $6831×1 trade | — |
| 2024 | — | $10K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Jul 29, 2025, Vanessa Carle reported holding 750 shares of Lexaria Bioscience (LEXX). At the last close of $4 on Nov 20, 2026, that is about $3K. This is the stake disclosed in filings, not a net worth.
No public filing gives Vanessa Carle's net worth. What SEC Form 4 shows is the stock stake: 750 shares of Lexaria Bioscience (LEXX), about $3K at the last close. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
Vanessa Carle bought shares on the open market in 2025. Sales in 1 of the 3 years since 2024.
In SEC filings since 2024: the latest open-market purchase is from 2025; the latest open-market sale is from 2024.
Lexaria Bioscience (LEXX), from 2024 to 2025: 1 purchase and 1 sale.
Vanessa Carle reported 1 open-market purchase and 1 sale here, 2024 to 2025.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.